{"ticker": {"uuid": "fba25610-a8c7-4c2f-bde0-de7e8658d193", "symbol": "600267", "name": "Zhejiang Hisun Pharmaceutical Co., Ltd.", "exchange": "SHH", "country": "CN", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Price to earnings forward of Zhejiang Hisun Pharmaceutical Co., Ltd. Class A \u2013 SSE:600267", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOcFBtY1lrdUJuSlJJV3loQ2RxMEZhblR6bmRrMDZSU21MMlhVbThjVkI5WE1SY05OQ3ktcE1MNWJ4OExnbEtYdXlyOEV6Z21IdldKSDJIbElCbllZTVNKVmFiQ2MwWkpFT2VtbzdHYWd4VzFvUTJzVWRDOXFMLUVpanpxOXdPMEJtb3R5WXU2cFg4MnVHdllXLS0xYTJibkRK?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T13:22:33+00:00", "published_display": "10 Jul 2026 13:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Haisco Pharmaceutical (600267.SH) announced its 2025 annual performance, with a net profit attributable to shareholders of 541 million yuan, representing a year-on-year decrease of 10.06%.", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQndtV2diMUlLWU1LUjcwVDFjWTVhLVhrOFM0X3MzendBQm9VZ2FqbzVuRTFPZDQtbmRNa0RYTkszWV9aa0tlUGRtdzMxcFM1NGFGVE5hWFVuQnduZkZQejhaUVJDU0FUTVJ3V2NmVDZTZnZ5LTVGQjJOLW0tV2ZkUkI1VjQyX1daR3B2NmQ0eWk3aG50cVR4WE83Z1lraTdvMWRVYko2ZEJjR1d1LVVBc0I2cFlwaFE?oc=5", "source_name": "Moomoo", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhejiang Hisun Pharmaceutical Co., Ltd.: Free of COVID-19, Governments Suggest Favipiravir", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNYTIzcTVUMVlUVTJ4czFmOFJYLXl3MHNueVNXb1l1ZjRNbDZwc1NvMkllcTE3OFZWYXdKQWhFbjFybkMyeHp6ZS1mZ2F2SXJNUXhPdTE0aVdhZjBzTjBvRkRuZXRRdmJiUXJTYXZFdmluU3F2ZDFOcGNVWEY3RHgwQ2xCTDZ0YklsV0F6WUUtS2JxMU02Ry0td2todXd2TlRCTEtLNDlhTGxGdjc3QTBhZFhxQ3ZDQ3VGOXNpdWF1bTRhN1FMMnNra1FNX1UxT3JYTEoxRV9zeDQ4SHkt?oc=5", "source_name": "Business Wire", "published_at": "2020-06-26T07:00:00+00:00", "published_display": "26 Jun 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxPVm9YU1JzN3JQRjdfckppSzREZDhWWEk3RUxjd0dzZGMteVBfOW96a1N6ZHJJejZSUEJpcnlpYnc5TnozZ0hBdVdzZzlfUXA2bzFId2VVdEZaVzNjX1lIUzdhWmVLOXdjcklsS0o2bldQRXV3N3dOVlJVOEFxcjdmck1GOE1pRVAwSnRWT0hydWVLR3laU2JMbGY2dmR2RXkzaUdIXzlnVFZvbmZGU3N2WV9UU05qSzhIdTJORm9LbjR2cWFoYWJKbjlSMXp6a1NQVGx1Z1lETFo2UHAxTWhHWTVxQnkyVmFUdmZkTUIzN2trZlZ0SHY4SzRpZVB1M0RESC11U0NhRXA4OUxfbmwzSTVJcldxUQ?oc=5", "source_name": "PR Newswire", "published_at": "2020-03-19T07:00:00+00:00", "published_display": "19 Mar 2020 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PAG acquires control of Hisun BioRay", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPOEctVlcxTFIwRUwzUjB5WHRkbTlucmlJY096LWFkd3FDTUdBRFE1aE5LbTVocDBxaFo1SERFcXVKaUxlWVpza1B0SXdyQV9EMnF2T3VnY2pHQ1NDQ0phTnUycTlEVG1HVEpaWXlKT3NsbFVRa3RRbEZubU9GWXFQUQ?oc=5", "source_name": "Asset Publishing and Research Limited", "published_at": "2019-09-05T07:00:00+00:00", "published_display": "05 Sep 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China's Zhejiang Hisun picks up new U.S. deal despite FDA troubles", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQRGs5d2N5SHJsV0hGYUVqazZEd1BhdWMtaUlhOWZOU0k4NHZadU9IZFktMDAzZUdVT0pBNFRHRkQ0TjU2OHNfRnpHeXJGdFFKVlF2Y19veE5IUXpEdkFXMDlHbXYzMkVpMmlKcUh6UXNaUjNlSW01cFhUazgtZmZrT0Z6TV9YbWpSWkg2X1RFanpQeGxIenpXYnFqQ1I2UmNubkgwbjVUV2hSUQ?oc=5", "source_name": "Fierce Pharma", "published_at": "2016-08-10T07:00:00+00:00", "published_display": "10 Aug 2016 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOZ3g0YWRUaDM4WS1odTdteGRndExhTXFFYTkzbGNFZ2JzV3RhSjhyZk5ISVk4UFo0OXlHSmJodjlaNHZaempKVVc4dFozenplbHkzXzA4OU55UmhET3pyazRsUnVBMEZYbURkQ1djUnVFVmhnLTdaUjNXdUNpZXk0SWlvaXBJTnFYQV8xcG4xd1NjWVp5VnVJRGhLWXR6a0FqLUZOS044bkk4a2VpcFJ2N19CZGVTYWVORkJiN3FDU0xiZVFQVWJ3?oc=5", "source_name": "Fierce Pharma", "published_at": "2016-06-22T07:00:00+00:00", "published_display": "22 Jun 2016 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer & Hisun Pharma To Jointly Develop Off-Patent Generics In China", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxObTNaRm84UFRXVDlIcnMyT3FRMXc1NTNWSjM3SXBEUUpVLWRnVW5KdmJEY2QtMEstMHdnbXVtMzZ4eEJRSkFuQTEtdkYwbnhsVy1PbmpDTS1jTjhTNndtaEhQRlQ2SkRaZXYwaE5QclJ0TUoybjN3QzNiLUlOckR0cDNXYlZ4anZHUzY0QWJGZ0p1VUdPNWJwMlhvSXhraWQxTjN5QTNpRUpjOXJLTjBwZHVFc0Z6b2ZUM1VFcGlRLWtORWNYOXB4M2VQMk0zdw?oc=5", "source_name": "Asian Scientist Magazine", "published_at": "2012-02-22T08:00:00+00:00", "published_display": "22 Feb 2012 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Zhejiang Hisun Pharmaceutical Co., Ltd. Class A \u2013 SSE:600267", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOcFBtY1lrdUJuSlJJV3loQ2RxMEZhblR6bmRrMDZSU21MMlhVbThjVkI5WE1SY05OQ3ktcE1MNWJ4OExnbEtYdXlyOEV6Z21IdldKSDJIbElCbllZTVNKVmFiQ2MwWkpFT2VtbzdHYWd4VzFvUTJzVWRDOXFMLUVpanpxOXdPMEJtb3R5WXU2cFg4MnVHdllXLS0xYTJibkRK?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T13:22:33+00:00", "published_display": "10 Jul 2026 13:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Haisco Pharmaceutical (600267.SH) announced its 2025 annual performance, with a net profit attributable to shareholders of 541 million yuan, representing a year-on-year decrease of 10.06%.", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQndtV2diMUlLWU1LUjcwVDFjWTVhLVhrOFM0X3MzendBQm9VZ2FqbzVuRTFPZDQtbmRNa0RYTkszWV9aa0tlUGRtdzMxcFM1NGFGVE5hWFVuQnduZkZQejhaUVJDU0FUTVJ3V2NmVDZTZnZ5LTVGQjJOLW0tV2ZkUkI1VjQyX1daR3B2NmQ0eWk3aG50cVR4WE83Z1lraTdvMWRVYko2ZEJjR1d1LVVBc0I2cFlwaFE?oc=5", "source_name": "Moomoo", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhejiang Hisun Pharmaceutical Co., Ltd.: Free of COVID-19, Governments Suggest Favipiravir", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNYTIzcTVUMVlUVTJ4czFmOFJYLXl3MHNueVNXb1l1ZjRNbDZwc1NvMkllcTE3OFZWYXdKQWhFbjFybkMyeHp6ZS1mZ2F2SXJNUXhPdTE0aVdhZjBzTjBvRkRuZXRRdmJiUXJTYXZFdmluU3F2ZDFOcGNVWEY3RHgwQ2xCTDZ0YklsV0F6WUUtS2JxMU02Ry0td2todXd2TlRCTEtLNDlhTGxGdjc3QTBhZFhxQ3ZDQ3VGOXNpdWF1bTRhN1FMMnNra1FNX1UxT3JYTEoxRV9zeDQ4SHkt?oc=5", "source_name": "Business Wire", "published_at": "2020-06-26T07:00:00+00:00", "published_display": "26 Jun 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxPVm9YU1JzN3JQRjdfckppSzREZDhWWEk3RUxjd0dzZGMteVBfOW96a1N6ZHJJejZSUEJpcnlpYnc5TnozZ0hBdVdzZzlfUXA2bzFId2VVdEZaVzNjX1lIUzdhWmVLOXdjcklsS0o2bldQRXV3N3dOVlJVOEFxcjdmck1GOE1pRVAwSnRWT0hydWVLR3laU2JMbGY2dmR2RXkzaUdIXzlnVFZvbmZGU3N2WV9UU05qSzhIdTJORm9LbjR2cWFoYWJKbjlSMXp6a1NQVGx1Z1lETFo2UHAxTWhHWTVxQnkyVmFUdmZkTUIzN2trZlZ0SHY4SzRpZVB1M0RESC11U0NhRXA4OUxfbmwzSTVJcldxUQ?oc=5", "source_name": "PR Newswire", "published_at": "2020-03-19T07:00:00+00:00", "published_display": "19 Mar 2020 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PAG acquires control of Hisun BioRay", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPOEctVlcxTFIwRUwzUjB5WHRkbTlucmlJY096LWFkd3FDTUdBRFE1aE5LbTVocDBxaFo1SERFcXVKaUxlWVpza1B0SXdyQV9EMnF2T3VnY2pHQ1NDQ0phTnUycTlEVG1HVEpaWXlKT3NsbFVRa3RRbEZubU9GWXFQUQ?oc=5", "source_name": "Asset Publishing and Research Limited", "published_at": "2019-09-05T07:00:00+00:00", "published_display": "05 Sep 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China's Zhejiang Hisun picks up new U.S. deal despite FDA troubles", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQRGs5d2N5SHJsV0hGYUVqazZEd1BhdWMtaUlhOWZOU0k4NHZadU9IZFktMDAzZUdVT0pBNFRHRkQ0TjU2OHNfRnpHeXJGdFFKVlF2Y19veE5IUXpEdkFXMDlHbXYzMkVpMmlKcUh6UXNaUjNlSW01cFhUazgtZmZrT0Z6TV9YbWpSWkg2X1RFanpQeGxIenpXYnFqQ1I2UmNubkgwbjVUV2hSUQ?oc=5", "source_name": "Fierce Pharma", "published_at": "2016-08-10T07:00:00+00:00", "published_display": "10 Aug 2016 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOZ3g0YWRUaDM4WS1odTdteGRndExhTXFFYTkzbGNFZ2JzV3RhSjhyZk5ISVk4UFo0OXlHSmJodjlaNHZaempKVVc4dFozenplbHkzXzA4OU55UmhET3pyazRsUnVBMEZYbURkQ1djUnVFVmhnLTdaUjNXdUNpZXk0SWlvaXBJTnFYQV8xcG4xd1NjWVp5VnVJRGhLWXR6a0FqLUZOS044bkk4a2VpcFJ2N19CZGVTYWVORkJiN3FDU0xiZVFQVWJ3?oc=5", "source_name": "Fierce Pharma", "published_at": "2016-06-22T07:00:00+00:00", "published_display": "22 Jun 2016 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer & Hisun Pharma To Jointly Develop Off-Patent Generics In China", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxObTNaRm84UFRXVDlIcnMyT3FRMXc1NTNWSjM3SXBEUUpVLWRnVW5KdmJEY2QtMEstMHdnbXVtMzZ4eEJRSkFuQTEtdkYwbnhsVy1PbmpDTS1jTjhTNndtaEhQRlQ2SkRaZXYwaE5QclJ0TUoybjN3QzNiLUlOckR0cDNXYlZ4anZHUzY0QWJGZ0p1VUdPNWJwMlhvSXhraWQxTjN5QTNpRUpjOXJLTjBwZHVFc0Z6b2ZUM1VFcGlRLWtORWNYOXB4M2VQMk0zdw?oc=5", "source_name": "Asian Scientist Magazine", "published_at": "2012-02-22T08:00:00+00:00", "published_display": "22 Feb 2012 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 48, "total_relevant": 8, "sentiment_summary": {"positive": 2, "negative": 0, "neutral": 6, "score": 54, "total": 8, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 2.75, "count": 5}, {"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 2, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 11.32, "latest_week": "2026-07-17", "one_week_move": 5.1, "four_week_move": 14.9, "twelve_week_move": 1.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.045178, "market_dynamics_buy_signal": false, "relative_strength": 11.408393, "fair_value_gap": 21.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 44.3353, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.1% over one week, +14.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Fierce Pharma", "count": 2}, {"label": "TradingView", "count": 1}, {"label": "Moomoo", "count": 1}, {"label": "Business Wire", "count": 1}, {"label": "PR Newswire", "count": 1}, {"label": "Asset Publishing and Research Limited", "count": 1}, {"label": "Asian Scientist Magazine", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 8}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 5}, {"label": "Earnings", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "8", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.1% over one week, +14.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Zhejiang Hisun Pharmaceutical Co., Ltd. Class A \u2013 SSE:600267"}], "updated_at": "2026-07-21T21:42:01.468401+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}